Denosumab, a rank ligand inhibitor for prevention of skeletal-related events due to bone metastases from solid tumors in adults.
Gail M
GM
Wilkes
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications* / Q000556:secondary*; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology; D000075202:Contraindications; D000069448:Denosumab; D004347:Drug Interactions; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced; D053245:RANK Ligand / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab